Apimeds, Inc. US Chief Operating Officer Robert Brooks PhD announced the company received a clearance letter from the US Food & Drug Administration on December 22nd authorizing the company to proceed with its Phase III clinical trial. Apimeds plans the launch of its Phase III Apitox, a honeybee toxin, for the indication of pain and inflammation of osteoarthritis early in 2011 with clincial sites in India and the United States.
Apimeds is a South Korean pharmaceutical dedicated to biological pharmaceutical products for unmet medical needs. This is the first US Phase III clinical trial for a Korean pharmaceutical company. The company continues to explore its Apitox product for the multiple sclerosis indication, but has not filed its intention to conduct a clinical trial for this indication. A Phase III clinical trial is the last development phase of clinical studies leading to submission of a new drug application in the US leading to marketing.
Robert Brooks PhD
Chief Operating Officer
Apimeds, Inc.
3418 Big Rd
Zieglerville, PA 19492
dbrooks@apimeds.com
No comments:
Post a Comment